Category: Moms

Anti-angiogenesis clinical trials

Anti-angiogenesis clinical trials

Developing Natural ways to boost energy levels biomarkers for diagnosing the Hydrostatic weighing for nutritional counseling and stage of cancer and Natural ways to boost energy levels mechanisms Anti-angiogenedis tumor angiogenesis Antu-angiogenesis drug resistance, clonical order to benefit drug selection, balance efficacy and toxicity, and simplify anti-cancer therapy. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Natl Acad. Inhibition of IL-6 normalized tumor vasculature, reduced hypoxia, and restored sensitivity to anti-VEGF therapy.

Anti-angiogenesis clinical trials -

Circulating VEGF also causes destructive effects in remote healthy tissues and organs, such as the bone marrow, liver, and spleen [ 44 ]. In this case, inhibition of VEGF-induced vascular impairment would potentially improve patient survival, as shown in preclinical models.

An important and clinically practical issue related to anti-angiogenic therapy is length of treatment. How long should a cancer patient be treated with anti-angiogenic drugs? What would happen if anti-angiogenic treatment was discontinued? Currently, no consensus exists regarding treatment timeline with anti-angiogenic drugs.

As an anti-angiogenic component is added to the standard chemotherapy regimen, anti-angiogenic therapy follows the timeline of chemotherapy. In clinical practice, anti-angiogenic treatment will inevitably be discontinued. Additionally, anti-angiogenic treatment will likely result in adverse effects that make therapy withdrawal difficult.

Similarly, if patients acquire drug resistance during treatment, this can also result in discontinuation of therapy.

In animal cancer models, discontinuation of anti-angiogenic therapy resulted in rapid regrowth of tumor blood vessels [ 45 ]. For small chemical compound-based drugs, revascularization occurs 2—3 days after drug withdrawal and reaches a maximal level around day 7.

Around this time, revascularization generates a rebound time window that drives angiogenesis to a level higher than it was prior to treatment [ 41 ]. It is possible that rebound angiogenesis reflects the time course of angiogenic vessel growth before vascular remodeling and maturation.

Effects of ON and OFF treatment with anti-angiogenic drugs on tumor vasculatures. Rapid revascularization and rebound angiogenesis can occur after treatment is discontinued. It is unclear if, after discontinuation of anti-angiogenic therapy, rebound angiogenesis also occurs in human patients.

However, reasonable speculation suggests that human tumors and mouse tumors would respond similarly. If rebound angiogenesis does occur in human cancer patients, discontinuation of anti-angiogenic therapy could potentially result in accelerated tumor growth.

Thus, non-stop, lifetime anti-angiogenic treatment should be recommended. In support of this view, prolonged anti-angiogenic therapy has resulted in prolonged survival for human cancer patients.

Originally, researchers believed that angiogenesis inhibitors, especially the endogenous inhibitors such as angiostatin, endostatin, and other generic inhibitors, would not develop drug resistance of tumor cells because they target endothelial cells rather than tumor cells [ 46 , 47 ]. Unlike malignant cells, endothelial cells, even those located in tumor tissues, have stable genomes and do not seem to use the canonical drug-resistant mechanisms.

However, both experimental and clinical findings have challenged this view. Some studies showed that endothelial cells in angiogenic tumor vessels contain aberrant genomes that would not be present in healthy vasculatures [ 48 ].

It is unclear if the tumor-like aberrant genetic information in endothelial cells is transferred from tumor cells or if the intrinsic development genomic instability develops in endothelial cells.

Inhibition of tumor angiogenesis could alter the cellular and molecular components in the tumor microenvironment, leading to development of drug resistance. For example, anti-angiogenic drug—induced vascular regression in the tumors creates tissue hypoxia in a local microenvironment, which augments expression levels of multiple angiogenic factors unrelated to the drug targets [ 36 , 49 ].

Investigators have shown that anti-VEGF drugs develop resistance of tumor cells by this compensatory mechanism. Moreover, anti-VEGF drugs also tip the balance between various cellular compositions, including inflammatory cells and stromal fibroblasts, which are important sources of cytokines and non-VEGF angiogenic factors that contribute to drug resistance [ 50 , 51 ].

Alternative mechanisms of tumor neovascularization that are not affected by drug targets also contribute to anti-angiogenic drug resistance. For example, vessel co-option, vascular mimicry, intussusception, and vasculogenesis support tumor growth and potentially inhibit anti-angiogenic treatment [ 10 , 37 , 52 — 54 ].

In patients who demonstrate intrinsic resistance to anti-VEGF therapy, non-VEGF angiogenic factors probably stimulate angiogenesis in their tumors.

Thus, combination therapeutic approaches that target different angiogenesis signaling pathways would likely be more effective. Also, patients who take multi-targeted drugs such as TKIs would be less likely to develop drug resistance.

Importantly, cross-communication between different angiogenic signaling pathways can generate synergistic effects, even though expression levels of each individual factor are low.

For example, the synergistic effects between FGF receptor 2 and PDGF-BB on angiogenesis promote tumor growth and metastasis [ 55 , 56 ]. In clinical practice, combination therapy represents a major mechanistic challenge [ 57 ]. Why would clinical benefits be achieved by combining anti-angiogenic drugs with chemotherapy?

Why would anti-angiogenic treatment alone be sufficiently effective? A few possible hypotheses may explain the mechanism underlying combination therapy. One hypothesis suggests that treatment with anti-angiogenic drugs produces a normalized vascular phenotype, which increases vascular perfusion rather than decreases it [ 58 ].

In the presence of chemotherapeutic agents, increased vascular perfusion enables more cytotoxic drugs to reach the tumors, leading to increased tumor cell death. In other words, when administered with chemotherapeutics, anti-angiogenic treatment inhibits tumor growth.

Also, the results of animal tumor models have demonstrated that anti-angiogenic drug-induced vascular normalization occurs within a limited time during treatment i. The mechanism underlying how combination therapy relates to vascular normalization is a paradox.

If anti-angiogenic drugs induce vascular normalization and possibly blood perfusion in tumors, tumor growth would be accelerated.

However, in both preclinical cancer models and clinical cancer patients, anti-angiogenic treatment does not promote tumor growth, although some researchers have suggested that the treatment facilitates cancer invasion [ 60 , 61 ].

Another experimental study suggested that the mechanism underlying combination therapy can be explained by a decrease of chemotherapeutic toxicity [ 62 ]. Chemotherapeutics produce a broad spectrum of toxicity, including suppression of bone marrow hematopoiesis and high levels of circulating VEGF.

Many cancer patients have high levels of circulating VEGF and manifest anemia [ 63 ]. A causal relationship between VEGF and anemia in human cancer patients has yet to be established, but studies of animal cancer models have shown that tumor-derived high-circulating VEGF causes severe anemia [ 44 ].

In high VEGF-producing tumor-bearing mice, chemotherapy and VEGF synergistically suppressed bone marrow hematopoiesis, resulting in early death [ 62 ]. Anti-VEGF treatment ablates VEGF-induced anemia and thus increases tolerance of chemotoxicity. Anti-angiogenic drugs recover bone marrow hematopoiesis prior to chemotherapy and increase tolerance of chemotoxicity [ 62 ].

If this regimen were approved for at least a subset of human cancer patients, it would probably result in substantially increased survival benefits for these patients. Mono-specific anti-VEGF drugs such as bevacizumab target only VEGF without binding to other proteins.

VEGF expression levels would serve as a reliable predictive marker for selecting cancer patients who are likely to benefit from anti-VEGF therapy. Based on more than 10 years of clinical experience with various cancer types, simply measuring VEGF expression levels, in either the circulation or tumor biopsies, has not fulfilled the criterion for predicting responders [ 64 — 68 ].

Why would VEGF, as the sole target for bevacizumab, not serve as a reliable predictive marker for patient selection? There is no satisfactory answer to this puzzling question.

However, some researchers have suggested that measuring different isoforms of VEGF might more reliably predict responders of anti-VEGF therapy [ 69 — 71 ].

Smaller VEGF isoforms, including VEGF, lack heparin-binding affinity and diffuse distally from their productive sites. Additionally, proteolytically processed smaller versions of VEGF can also lack high heparin-binding affinity and can be transported to distal tissues and organs. Interestingly, these small versions of VEGF proteins have some predictive values, although their targets may not be limited to tumor tissues.

It is possible that off-tumor targets of these small VEGF proteins predict their therapeutic values [ 22 ]. Indeed, based on preclinical and clinical findings, the potentially beneficial effects of anti-VEGF drug off-tumor targets have been proposed [ 22 ].

Many physiological, cellular, and molecular biomarker candidates related to anti-angiogenic therapy-induced adverse effects have been proposed, but in clinical practice physiological responses are the most commonly used biomarkers.

For example, anti-angiogenic drug-induced hypertension has been associated with clinical benefits; however, the molecular mechanism underlying the benefit is unknown [ 72 — 78 ].

Given that adding anti-angiogenic components to conventional chemotherapy is widely used for the treatment of cancer, significant clinical benefits without selection biomarkers are truly valuable.

Assuming a reliable predictive biomarker exists, treating a selected population of responders with anti-angiogenic drugs would likely markedly increase clinical benefits. Future efforts should focus on identifying such a reliable biomarker for clinical use. Systemic delivery of anti-angiogenic drugs to cancer patients would inevitably expose non-cancerous healthy tissues to these drugs [ 40 , 41 ].

In preclinical studies, investigators have shown that systemic treatment induces vascular changes in multiple tissues and organs. Additionally, anti-VEGF therapy caused a marked reduction in micro vasculatures in the liver, kidney, and gastrointestinal wall [ 40 , 41 ]. Vascular changes in non-tumor tissues are associated with clinical adverse effects, including hypertension, hypothyroidism, gastrointestinal perforation, and cardiovascular disease [ 15 , 79 ].

Since VEGF is an important hemostatic factor for maintaining the number and structure of microvessels in various tissues and organs, it is perhaps not surprising that anti-VEGF-based anti-angiogenic drugs would cause broad adverse effects.

How would anti-angiogenic drugs be directly delivered to tumorous tissues without affecting the healthy vasculature? Designing a new generation of targeted drugs would be a very challenging task.

Even though anti-angiogenic drugs are locally injected into tumorous tissues, they still enter the circulation. Additionally, this approach would prevent anti-angiogenic agents from reaching metastatic tumors.

In fact, clinical indications of using anti-angiogenic therapies approved by the U. FDA often include metastatic disease. Inhibition of angiogenesis for the treatment of cancer has been successfully translated into clinical use.

The key issue is that patients who receive anti-angiogenic drugs experience relatively few clinical benefits. For patients with some cancer types, including pancreatic cancer and breast cancer, the addition of an anti-angiogenic component to chemotherapy has not produced meaningful improvement in overall survival.

If all solid tumor growth depends on angiogenesis, why would anti-angiogenic treatments not be beneficial? Why would anti-angiogenic monotherapies fail to demonstrate clinical benefits? What is the mechanistic rationale of combination therapy with chemotherapeutics?

Could a predictive marker be identified? How long should cancer patients be treated with anti-angiogenic drugs? What could happen if the anti-angiogenic therapy is discontinued?

Would combinations of drugs that target different angiogenic pathways improve therapeutic outcomes? There are no unified opinions on these clinical issues. Possibly, an important means to address these issues is to establish clinically relevant cancer models in animals. Given sophisticated cancer biology, metastatic disease, and systemic disorders in cancer patients, the complex mechanisms underlying malignant disease cannot likely be simply explained.

The same type of cancer in different patients may represent a different disease. Likewise, the same cancer in the same patient may represent a different disease at different stages of progression.

This means that personalized medicine may not be sufficiently effective and that dynamic approaches should be developed for treating cancer at different stages during disease development.

In clinical practice, developing both personalized therapy and dynamic therapy is an extremely challenging task. Forty-year journey of angiogenesis translational research. Sci Transl Med. Article PubMed Google Scholar. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med.

Article CAS PubMed Google Scholar. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. Cao Y, Langer R. Optimizing the delivery of cancer drugs that block angiogenesis. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.

Cao Y, Xue L. Semin Thromb Hemost. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol. Folberg R, Hendrix MJ, Maniotis AJ.

Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. Article PubMed Central CAS PubMed Google Scholar. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.

Bissell MJ. Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? Ribatti D, Vacca A, Dammacco F. New non-angiogenesis dependent pathways for tumour growth.

Eur J Cancer. Leenders WP, Kusters B, de Waal RM. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Dome B, Paku S, Somlai B, Timar J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance.

J Pathol. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

Haines IE, Miklos GL. Paclitaxel plus bevacizumab for metastatic breast cancer. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat Rev Endocrinol. Off-tumor target—beneficial site for antiangiogenic cancer therapy? Nat Rev Clin Oncol. Fidler IJ.

Cancer metastasis. Br Med Bull. CAS PubMed Google Scholar. Lee SL, Rouhi P, Dahl Jensen L, Zhang D, Ji H, Hauptmann G, et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model.

Proc Natl Acad Sci USA. Rouhi P, Jensen LD, Cao Z, Hosaka K, Lanne T, Wahlberg E, et al. Hypoxia-induced metastasis model in embryonic zebrafish. Nat Protoc. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ.

Cancer cachexia: understanding the molecular basis. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia.

Eur J Pharmacol. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, et al. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M.

Characterization of a cancer cachectic factor. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer VENICE : a phase 3, double-blind randomised trial.

Lancet Oncol. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy REVEL : a multicentre, double-blind, randomised phase 3 trial.

Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. Cao Y, Zhong W, Sun Y. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Semin Cancer Biol.

Tumor angiogenesis and molecular targets for therapy. Front Biosci Landmark Ed. Article CAS Google Scholar. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK.

Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. Sitohy B, Nagy JA, Jaminet SC, Dvorak HF. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Cancer Res. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. Yang Y, Zhang Y, Cao Z, Ji H, Yang X, Iwamoto H, et al.

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, et al. Thyroid hormone inactivation in gastrointestinal stromal tumors. Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, et al.

Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase ix in human tumours. J Clin Pathol. Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.

Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. Angiogenesis in cancer, vascular, rheumatoid and other disease.

Nat Med. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Ghosh K, Thodeti CK, Dudley AC, Mammoto A, Klagsbrun M, Ingber DE. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro.

Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Cancer Cell. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.

Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, et al. The hypoxic response of tumors is dependent on their microenvironment. Stacker SA, Achen MG.

The vegf signaling pathway in cancer: the road ahead. Chin J Cancer. PubMed Central CAS PubMed Google Scholar. Chen YS, Chen ZP.

Vasculogenic mimicry: a novel target for glioma therapy. Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, et al.

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, et al.

Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.

Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al.

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Zhang D, Hedlund EM, Lim S, Chen F, Zhang Y, Sun B, et al. Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Ribatti D. Erythropoietin and tumor angiogenesis. Stem Cells Dev. Garcia-Donas J, Rodriguez-Antona C, Jonasch E.

Molecular markers to predict response to therapy. Your gift will help support our mission to end cancer and make a difference in the lives of our patients. Our personalized portal helps you refer your patients and communicate with their MD Anderson care team. As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

Choose from 12 allied health programs at School of Health Professions. Learn about our graduate medical education residency and fellowship opportunities.

Angiogenesis is the process of creating new blood vessels. Some cancerous tumors are very efficient at creating new blood vessels, which increases blood supply to the tumor and allows it to grow rapidly. Cancer cells begin the angiogenesis process by sending signals to nearby tissue and activating growth factors that allow the tumor to form new blood vessels.

One such molecule is called vascular endothelial growth factor, or VEGF. Researchers developed drugs called angiogenesis inhibitors, or anti-angiogenic therapy, to disrupt the growth process.

These drugs search out and bind themselves to VEGF molecules, which prohibits them from activating receptors on endothelial cells inside blood vessels.

Bevacizumab Avastin ® works in this manner. It is used to treat glioblastoma and cancers of the lung , kidney , breast , colon and rectum.

Other angiogenesis inhibitor drugs work on a different part of the process, by stopping VEGF receptors from sending signals to blood vessel cells. These drugs are known as tyrosine kinase inhibitors TKI.

Sunitinib Sutent ® is an example of a tyrosine kinase inhibitor. For this reason, these drugs are typically used in combination with chemotherapy or other treatments. Angiogenesis inhibitors are particularly effective for treating liver cancer , kidney cancer and neuroendocrine tumors.

Since they act on blood vessel formation and not the tumor itself, the side effects of angiogenesis inhibitors are different than traditional chemotherapy drugs. My Chart. Donate Today.

Request an Appointment Request an Appointment New Patients Current Patients Referring Physicians. Manage Your Risk Manage Your Risk Manage Your Risk Home Tobacco Control Diet Body Weight Physical Activity Skin Safety HPV Hepatitis.

Family History Family History Family History Home Genetic Testing Hereditary Cancer Syndromes Genetic Counseling and Testing FAQs. Donate Donate Donate Home Raise Money Honor Loved Ones Create Your Legacy Endowments Caring Fund Matching Gifts.

Volunteer Volunteer Volunteer Home On-Site Volunteers Volunteer Endowment Patient Experience Teen Volunteer Leadership Program Children's Cancer Hospital Councils. Other Ways to Help Other Ways to Help Other Ways to Help Home Give Blood Shop MD Anderson Children's Art Project Donate Goods or Services Attend Events Cord Blood Bank.

Chinese Journal of Cancer volume 35Article number: 21 Cite Anti-angilgenesis article. Metrics details. In human Energy-efficient lighting, Natural ways to boost energy levels that Blackberry and peach salsa recipe tumor Anti-anfiogenesis growth are widely used Anti-ngiogenesis treat a variety Anti-angiogenesis clinical trials clinicsl types. Natural ways to boost energy levels climical phase 3 clinical Anti-angiogemesis have clinixal significant survival benefits; however, the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens. Treating cancer by blocking tumor angiogenesis, which was proposed by Judah Folkman nearly 45 years ago [ 12 ], is now a universally accepted mechanism. Anti-angiogenesis clinical trials

Author: Dozahn

0 thoughts on “Anti-angiogenesis clinical trials

Leave a comment

Yours email will be published. Important fields a marked *

Design by